Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (6) , 1161-1165
Abstract
Objectives Extension of disease beyond the atrioventricular (AV) node is associated with increased mortality in cardiac neonatal lupus (NL). Treatment of isolated heart block with fluorinated steroids to prevent disease progression has been considered but published data are limited and discordant regarding efficacy. This study evaluated whether fluorinated steroids given to manage isolated advanced block prevented development of disease beyond the AV node and conferred a survival benefit. Methods In this retrospective study of cases enrolled in the Research Registry for NL, inclusion was restricted to anti-SSA/Ro-exposed cases presenting with isolated advanced heart block in utero who either received fluorinated steroids within 1 week of detection (N=71) or no treatment (N=85). Outcomes evaluated were: development of endocardial fibroelastosis, dilated cardiomyopathy and/or hydrops fetalis; mortality and pacemaker implantation. Results In Cox proportional hazards regression analyses, fluorinated steroids did not significantly prevent development of disease beyond the AV node (adjusted HR=0.90; 95% CI 0.43 to 1.85; p=0.77), reduce mortality (HR=1.63; 95% CI 0.43 to 6.14; p=0.47) or forestall/prevent pacemaker implantation (HR=0.87; 95% CI 0.57 to 1.33; p=0.53). No risk factors for development of disease beyond the AV node were identified. Conclusions These data do not provide evidence to support the use of fluorinated steroids to prevent disease progression or death in cases presenting with isolated heart block.Keywords
This publication has 23 references indexed in Scilit:
- Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupusRheumatology, 2012
- Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi–Racial/Ethnic Registry of Anti-SSA/Ro–Associated Cardiac Neonatal LupusCirculation, 2011
- Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) StudyThe American Journal of Cardiology, 2009
- Perinatal Outcome of Fetal Atrioventricular BlockCirculation, 2008
- Treatment of fetal heart block with maternal steroid therapy: case report and review of the literatureUltrasound in Obstetrics & Gynecology, 2004
- Questions about dexamethasone use for the prevention of anti-SSA related congenital heart blockAnnals of the Rheumatic Diseases, 2003
- Maternal Anti-Ro and Anti-La Antibody–Associated Endocardial FibroelastosisCirculation, 2002
- Antenatal corticosteroids revisited: repeat courses— National Institutes of Health Consensus Development Conference Statement, August 17–18, 2000Obstetrics & Gynecology, 2001
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999